StockData
Immunome Inc. logo

Immunome Inc. (IMNM) income statement

IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q1 năm tài chính 2026, quý kết thúc ngày Mar 31, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$16.78−0.40 (-2.33%)

Close on Nov 18, 2026Market cap $1.91BP/E –Yield –

Immunome Inc. income statement

Ratios

Latest available, balances at Mar 31, 2026

Profitability, TTM

Gross margin
–
Operating margin
-5947.9%
Net margin
-5593.8%
Return on equity, FY2025
-52.1%

Financial strength

Current ratio
21.68
Debt to equity
–
Debt to assets
–
Cash to current liabilities
2125.7%

Valuation

P/E ratio
–
Price to sales
474.68
Price to book
3.24
Dividend yield
–

See a number that looks wrong?